GW-activated PPARβ/δ reduced the expression of α-SMA in SSc fibroblasts, while the co-treatment with either GSK or compound 10h (PPARβ/δ inverse agonist) increased the expression of α-SMA (Fig. 6i). Here, ACTA1 is linked to systemic sclerosis.